News for VistaGen Therapeutics, Inc. (VTGN)

Vistagen (VTGN) has provided a timeline update for its clinical trials under the PALISADE Phase 3 Program, which focuses on the acute treatment of social anxiet

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a notable transaction by acquiring 1,381,759 shares of Vistagen Therapeutics Inc at

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my VTGN stock update and a look ahead.

On December 31, 2024, StemPoint Capital LP (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 481,700 shares of Vistagen Therapeut

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ETCompany ParticipantsMark McPartland - Senior Vice...

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 8% and 35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Vistagen Therapeutics Inc (VTGN) is set to release its Q3 2025 earnings on Feb 13, 2025. The consensus estimate for Q3 2025 revenue is $0.18 million, and the ea

Vistagen reports promising PH284 nasal spray study

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ETCompany ParticipantsMark McPartland - SVP, IRShawn...

Research and Development Expenses: $10.2 million for the quarter ended September 30, 2024, compared to $3.9 million for the same period last year.General Admin

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of -5% and 45.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $183,000 for the quarter, falling short of the estimated $220,000.Net Loss: $13.0 million for the quarter, compared to $6.6 million in the same period

Vistagen Therapeutics Inc (VTGN) is set to release its Q2 2025 earnings on Nov 7, 2024. The consensus estimate for Q2 2025 revenue is $0.22 million, and the ear

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Research and Development Expenses: $7.6 million for the quarter ending June 30, 2024, compared to $4.2 million for the same period last year.General and Admini

Aug 13, 2024 / 09:00PM GMTOperator Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics fiscal year 2025 first-quarter corporate update conferen

MicroAlgo Inc. (MLGO) is up over 49% in Thursday's pre-market trading. The following are some of the stocks making big moves..

MicroAlgo Inc. (MLGO) is up over 49% in Thursday's pre-market trading. The following are some of the stocks making big moves..